Key result
Injectable magnetofluids enable seamless cardiac occlusion to reduce embolic risk in atrial fibrillation.
Why the study?
Managing long-term embolic risk in atrial fibrillation is challenging due to anatomical mismatch and thrombus risks with existing rigid metallic occluders.
Injectable magnetofluids are being explored as a novel, personalized approach for cardiac occlusion to manage embolic risk in atrial fibrillation, potentially overcoming limitations of rigid metallic occluders.
Managing long-term embolic risk in atrial fibrillation remains a major clinical challenge, while existing rigid metallic occluders are constrained by anatomical mismatch and persistent risks of device-related thrombus. Recent advances in personalized magnetofluidic systems introduce an
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question. Injectable magnetofluids provide a novel, personalized approach for seamless cardiac occlusion to manage long-term embolic risk in atrial fibrillation.
Synapse has enriched 5 related papers. Consider them for comparative context: